Moderna shares fell over 25%, wiping out $24 billion in value, following late-stage trial data showing its melanoma vaccine reduced recurrence risk by 42%. Analysts described the reaction as a typical
Moderna will replace Warner Bros. Discovery on the Nasdaq 100 index effective October 9, following a sixfold share price increase to a $75 billion valuation.
Moderna and Merck announced a breakthrough in mRNA cancer vaccine collaboration, marking the first late-stage success after over a century of failures. The vaccine showed efficacy in melanoma patients
The U.S. Treasury doubled bond buybacks to stabilize debt markets, while Moderna and Merck surged on a cancer vaccine breakthrough. Middle East conflicts reduced refining capacity, driving European di
Asian stocks are set to rebound following US Treasury plans to boost bond buybacks, while commodities like oil and gold saw gains. Corporate highlights include Moderna and Merck's successful melanoma
Moderna and Merck reported positive Phase III trial results for a personalized mRNA melanoma vaccine, cutting recurrence risk by half. This breakthrough validates mRNA technology for oncology, with fu
Moderna and Merck announced successful late-stage trial results for their combined melanoma treatment, reducing cancer recurrence and spread. Following the data, Moderna shares surged 60% while Merck
CureVac sued Moderna in Delaware federal court, alleging patent infringement on its mRNA vaccine technology and requesting royalties. This lawsuit adds to a wave of high-stakes intellectual property d
Syngenta halts paraquat production and Moderna settles a lipid patent dispute, while Middle East geopolitical tensions threaten Gulf supplies of LNG, urea, and polyethylene derivatives.
ChemBrief